Royalty Pharma (RPRX) P/B ratio
Royalty Pharma (RPRX) trades at 6.0× its book value per share at the end of fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/B ratio was 3.4×. That is 54.4% higher than the 2.2× of fiscal 2024. Figures as of 18 Nov 2026, 07:38 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- P/B ratio today
- 6.0×
- P/B ratio, fiscal 2025
- 3.4×
- Change on fiscal 2024
- +54.4%
- Highest on record
- 3.4×fiscal 2025
- Lowest on record
- 1.6×fiscal 2021
- Fiscal years on record
- 62020–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.
Royalty Pharma P/B ratio, in more detail
Today's figure is 77.7% above the fiscal 2025 year-end.
Across the 6 fiscal year-ends on record (2020–2025), the highest was 3.4× in fiscal 2025 and the lowest 1.6× in fiscal 2021. Today's P/B ratio is above every one of the 6 fiscal year-ends on record; their median is 2.4×.
P/B ratio at each fiscal year-end
The last point is today's figure; the others are fiscal year-ends.
Royalty Pharma P/B ratio, year by year
| Fiscal year | P/B ratio | Change | Year ended | Share price at year-end | Book value per share |
|---|---|---|---|---|---|
| Today | 6.0× | — | $68.68 | — | |
| 2025 | 3.4× | 54.4% up | $38.64 | $11.47 | |
| 2024 | 2.2× | 15.9% down | $25.51 | $11.69 | |
| 2023 | 2.6× | 15.6% down | $28.09 | $10.83 | |
| 2022 | 3.1× | 90.7% up | $39.52 | $12.85 | |
| 2021 | 1.6× | 15.1% down | $39.85 | $24.71 | |
| 2020 | 1.9× | — | $50.05 | $26.36 |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
The P/B ratio is the share price divided by book value per share — shareholders' equity on the balance sheet divided by the share count — at each fiscal year-end; a year with negative equity has no P/B.
How to read it
It compares the price with the accounting value of what the company owns net of what it owes, and matters most for banks, insurers and other balance-sheet businesses.
P/B ratio at health care companies of similar size
| Company | P/B ratio |
|---|---|
| IQVIA Holdings IQV | 6.5× |
| Revolution Medicines RVMD | 21.6× |
| Royalty Pharma RPRX | 6.1× |
| Biogen BIIB | 2.0× |
| GE HealthCare Technologies GEHC | 3.6× |
| Alcon ALC | 1.6× |
Today's market value divided by shareholders' equity at the latest fiscal year-end. A company whose statements are in another currency than its shares is left out.
Royalty Pharma, figure by figure
- Royalty Pharma market cap
- Royalty Pharma revenue
- Royalty Pharma earnings
- Royalty Pharma earnings per share (EPS)
- Royalty Pharma P/E ratio
- Royalty Pharma P/S ratio
- Royalty Pharma free cash flow
- Royalty Pharma operating margin
- Royalty Pharma dividend
- Royalty Pharma shares outstanding
- Royalty Pharma total debt
- Royalty Pharma cash on hand
- Royalty Pharma total assets
- Royalty Pharma return on equity (ROE)
- Royalty Pharma return on invested capital (ROIC)
Royalty Pharma (RPRX) overview: price, valuation and scorecardAll health care companies by market value
Royalty Pharma P/B ratio: questions and answers
What is Royalty Pharma's P/B ratio?
Royalty Pharma (RPRX) trades at 6.0× its book value per share at the end of fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/B ratio was 3.4×. That is 54.4% higher than the 2.2× of fiscal 2024.
Is Royalty Pharma's P/B ratio high or low compared with its own history?
Today's P/B ratio is above every one of the 6 fiscal year-ends on record; their median is 2.4×.
What are the highest and lowest P/B ratio figures on record for Royalty Pharma?
Across the 6 fiscal year-ends on record (2020–2025), the highest was 3.4× in fiscal 2025 and the lowest 1.6× in fiscal 2021.
How is Royalty Pharma's P/B ratio calculated?
The P/B ratio is the share price divided by book value per share — shareholders' equity on the balance sheet divided by the share count — at each fiscal year-end; a year with negative equity has no P/B.
Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.
Learn: P/B ratio
All stocks guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- Piotroski F-score: the nine tests and what they show
The Piotroski F-score is a 0–9 count of simple accounting tests a company passes: four on profitability, three on debt, liquidity and share issuance, two on operating efficiency. Joseph Piotroski's 2000 paper found that among cheap, high book-to-market stocks, high scorers went on to beat low scorers. It is a screen of financial health, not a valuation.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
Cite this page
Funkfolio, “Royalty Pharma (RPRX) P/B ratio”, data as of 18 November 2026. https://funkfolio.com/stock/RPRX/pb-ratio
Underlying data: the company's filings with the SEC and Yahoo Finance.